Bicalutamide monotherapy for early stage prostate cancer: An update

Journal of Urology

Volumn 170, Issue 6 II, 2003, Pages

  Iversen, Peter ^a   Roach III, Mack ^b   Smith, Matthew R ^b   Carroll, Peter R ^b   Nelson, Joel B ^b   Higano, Celestia S ^b   Oh, William K ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Antiandrogens; Prostatic neoplasms; Quality of life

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GOSERELIN; PLACEBO;

ABDOMINAL PAIN; ACCIDENT; ALOPECIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE DENSITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; EARLY CANCER; FLU LIKE SYNDROME; FOLLOW UP; GYNECOMASTIA; HEMATURIA; HERNIA; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MONOTHERAPY; ORCHIECTOMY; PAIN; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SEXUAL FUNCTION; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN; WELLBEING;

EID: 0242440356     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000096491.61731.38     Document Type: Conference Paper

References (18)

1. Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E. et al: Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 49: 937, 2001
2. Hanks, G. E., Lu, J., Machtay, V., Venkatesan, V., Pinover, W., Byhardt, R. et al: RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol, 19: 327a, 2000
3. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O. et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 360: 103, 2002
4. Granfors, T., Modig, H., Damber, J. E. and Tomic, R.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol, 159: 2030, 1998
5. Prayer-Galletti, T., Zattoni, F., Capizzi, A., Dal Moro, F. and Pagano, F. on behalf of the study group: Disease free survival in patients with pathological "C Stage" prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol, 38: 504, 2000
6. Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D. and Trump, D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341: 1781, 1999
7. Kirby, R.: Treatment options for early prostate cancer. Urology, 52: 948, 1998
8. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
9. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H. and Tammela, T. L. J.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579, 2000
10. Iversen, P., Melezinek, I. and Schmidt, A.: Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int, 87: 47, 2001
11. See, W. A., McLeod, D., Iversen, P. and Wirth, M.: The bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol, 6: 43, 2001
12. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I. and Gleason, D.: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
13. Iversen, P., Wirth, M., See, W., McLeod, D., Morris, T. and Carroll, K.: Is the efficacy of hormonal therapy affected by lymph node status? New data from the bicalutamide EPC programme. Eur Urol, suppl., 1: 134, 2002
14. Wirth, M., McLeod, D., Iversen, P., See, W., Morris, T. and Carroll, K.: Efficacy of bicalutamide in early prostate cancer by initial disease stage and grade. J Urol, 167: 345, 2002
15. Iversen, P., Tammela, T., Vaage, S., Lukkarinen, O., Lodding, P., Bull-Njaa, T. et al: A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol, 42: 204, 2002
16. Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Garcia-Vargas, J. E., Gallo, J. and McFadden, S.: Bone mineral density is maintained during bicalutamide ('Casodex') treatment. Proc Am Soc Clin Oncol, 21: 196a, 2002
17. Tyrrell, C., Morris, T. and Carroll, K.: Prophylactic breast irradiation significantly reduces the incidence of bicalutamide-induced gynaecomastia. Eur Urol, suppl., 1: 136, 2002
18. Saltzstein, D., Cantwell, A., Sieber, P., Ross, J. R., Silvay-Mandeau, O. and Gallo, J.: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int, suppl., 90: 120, 2002